SCHEMBL2991010

SCHEMBL2991010

O=C(CCO)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 1.00
ALDH1A1 P00352 1/20 1.00
ABL1 P00519 1/20 1.00
POLB P06746 1/20 1.00
ALPI P09923 1/20 1.00
GAA P10253 1/20 1.00
ALPG P10696 1/20 1.00
APEX1 P27695 1/20 1.00
CASP3 P42574 1/20 1.00
RECQL P46063 1/20 1.00
BLM P54132 1/20 1.00
CASP7 P55210 1/20 1.00
CASP6 P55212 1/20 1.00
MCL1 Q07820 1/20 1.00
RIN1 Q13671 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
NPC1 O15118 1/20 0.71
RAB9A P51151 1/20 0.71
HSD17B3 P37058 8/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25706395 0.90 L3MBTL1 (0.81) KDM4EALDH1A1ABL1POLBALPI
SCHEMBL7939950 0.87 NPC1 (0.81) KDM4EALDH1A1ABL1POLBALPI
Ethylene Glycol SCHEMBL7803540 0.86 NPC1 (0.79) KDM4EALDH1A1ABL1POLBALPI
SCHEMBL7282654 0.86 NPC1 (0.79) KDM4EALDH1A1ABL1POLBALPI
SCHEMBL8733595 0.83 NPC1 (1.00) KDM4EALDH1A1ABL1POLBALPI
SCHEMBL124008 0.83 NPC1 (0.91) KDM4EALDH1A1ABL1POLBALPI
SCHEMBL8614024 0.81 NPC1 (0.86) KDM4EALDH1A1ABL1POLBALPI
SCHEMBL8519713 0.81 NPC1 (0.86) KDM4EALDH1A1ABL1POLBALPI
SCHEMBL8622942 0.81 NPC1 (0.86) KDM4EALDH1A1ABL1POLBALPI
SCHEMBL10341631 0.81 NPC1 (0.86) KDM4EALDH1A1ABL1POLBALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3106522-B1 METHOD FOR PRODUCING PHENYL PROPANE-BASED COMPOUNDS USING ENZYMES JAPAN AGENCY MARINE EARTH SCI (JP) 2021-09-22 EP claimed
EP-3106523-B1 METHOD FOR PRODUCING PHENYL PROPANE-BASED COMPOUND USING MICRO-ORGANISMS JAPAN AGENCY MARINE EARTH SCI (JP) 2021-06-23 EP claimed
EP-3106522-A1 METHOD FOR PRODUCING PHENYL PROPANE-BASED COMPOUNDS USING ENZYMES Japan Agency for Marine-Earth Science and Technology (JP) 2016-12-21 EP claimed
EP-3106523-A1 METHOD FOR PRODUCING PHENYL PROPANE-BASED COMPOUND USING MICRO-ORGANISMS Japan Agency for Marine-Earth Science and Technology (JP) 2016-12-21 EP claimed
US-20160348135-A1 METHOD FOR PRODUCING PHENYL PROPANE-BASED COMPOUND USING MICROORGANISMS JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY (JP) 2016-12-01 US claimed
US-20160348136-A1 METHOD FOR PRODUCING PHENYL PROPANE-BASED COMPOUNDS USING ENZYMES JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY (JP) 2016-12-01 US claimed
US-20080255228-A1 Ascorbic Acid Complexes for Skin Care Including Treatment of Dark Skin & Wrinkles BIODERM RESEARCH (US) 2008-10-16 US claimed
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction BIODERM RESEARCH (US) 2008-10-16 US claimed
US-7427690-B2 Multifunction “crown complexes” from amino acids and peptides for skin and hair restoration BIODERM RESEARCH (US) 2008-09-23 US claimed
US-20070099886-A1 Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration BIODERM RESEARCH (US) 2007-05-03 US claimed
US-20060074108-A1 Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition BIODERM RESEARCH (US) 2006-04-06 US claimed
US-20050271608-A1 Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives GUPTA SHYAM K 2005-12-08 US claimed
JP-57156294-A None JP disclosed
CN-117919217-A Pharmaceutical composition for treating parkinsonism and preparation method thereof 浙江华海药业股份有限公司 2024-04-26 CN disclosed
WO-2024078607-A1 PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND PREPARATION METHOD THEREFOR 浙江华海药业股份有限公司 2024-04-18 WO disclosed
CN-116948853-A Engineering bacterium for preparing salidroside and tyrosol by efficient fermentation and application thereof 安徽普利药业有限公司 2023-10-27 CN disclosed
EP-0653455-A1 FILM FOR METAL LAMINATION TEIJIN LIMITED (JP) 1995-05-17 EP disclosed
EP-0108822-B1 ANTIGLAUCOMA COMPOUNDS USV PHARMACEUTICAL CORPORATION (US) 1986-08-13 EP disclosed
EP-0108822-A1 Antiglaucoma compounds USV PHARMACEUTICAL CORPORATION (US) 1984-05-23 EP disclosed
JP-S57156294-A HEAT-SENSITIVE RECORDING MATERIAL RICOH CO LTD 1982-09-27 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction PSMB1, PLOD3, CUTA KDM4E 513/4885ALDH1A1 330/4885ABL1 2802/4885
US-20080255228-A1 Ascorbic Acid Complexes for Skin Care Including Treatment of Dark Skin & Wrinkles PROC, COL1A1, CUTA KDM4E 1689/4885ALDH1A1 35/4885ABL1 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.